my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
04-20-2005: Applied Biosystems, an Applera Corporation business, announced a joint, research protocol with the Cohort Consortium of the National Cancer Institute (NCI), one of the largest cohorts performing disease association studies. The protocol is being applied to discover inherited gene variants in research samples taken from patients with breast and prostate cancer, and assess the genetic variants and behavioral and environmental factors associated with the development of these cancers.
The NCI Cohort Consortium is using Applied Biosystems TaqMan® SNP Genotyping Assays and 7900HT Real-Time PCR Systems to identify novel inherited gene variants that may contribute to the development of these two cancers. The study combines the resources of six large prospective cohort studies across 10 centers and includes samples from more than 6,000 breast and 8,000 prostate cancer patients. The SNP genotyping assays designed by Applied Biosystems and used by the NCI Cohort Consortium will be made public to researchers online.
"Coordinating and standardizing genotyping activities across such a large-scale, multi-center consortium are essential to obtaining consistent, meaningful data," said Brian E. Henderson, M.D., Dean of the Keck School of Medicine, University of Southern California. "We believe the collaboration between Applied Biosystems and the Cohort Consortium for breast and prostate cancer serves as a model for other large-scale, genetic association studies."
"Exploring how genetic variation influences susceptibility in complex diseases, such as breast and prostate cancer, is critical to the development of effective therapies," said Dennis A. Gilbert, Ph.D., Chief Scientific Officer for Applied Biosystems. "We are excited about this opportunity to apply our genotyping tools to advance targeted medicine."
Watchlist
This is where you can add this news to your personal favourites
Additional Information
Applied Biosystems Deutschland GmbH holds 95% of GENEART Shares
The majority shareholder of GENEART AG, Regensburg, Applied Biosystems Deutschland GmbH, Darmstadt ("ABD"), directly holds more than 95% of all shares in GENEART AG as noticed by ABD. ABD informed the management board of GENEART AG about this fact by letter dated August/3/2010. By virtue o ... more
GENEART AG and Applied Biosystems Deutschland GmbH intend to conclude a domination agreement
GENEART AG and its majority shareholder, Applied Biosystems Deutschland GmbH, intend to conclude a domination agreement pursuant to Section 291 et seq. German Stock Corporation Act (Aktiengesetz) with GENEART AG as the dominated entity and Applied Biosystems Deutschland GmbH as the dominati ... more
Management Board and Supervisory Board of GENEART Recommends Acceptance of Voluntary Public Offer
The Management Board and the Supervisory Board of GENEART AG have announced their joint statement with respect to the voluntary public offer by Applied Biosystems Deutschland GmbH to the shareholders of GENEART AG. This joint statement is in reference to the offer document published by the ... more
Applied Biosystems Deutschland GmbH
Applied Biosystems, Applera Deutschland GmbH, is a leading supplier for life science technology in the field of genomics, proteomics, high throughput screening and laboratory information management systems (LIMS). more
Applied Biosystems has demonstrated its position as a technology leader and driving force in the changing dynamics of the life science marketplace. The Applied Biosystems business is focused on the following markets: basic research, commercial research (pharmaceutical and biotechnology) and ... more
Applied Biosystems has demonstrated its position as a technology leader and driving force in the changing dynamics of the life science marketplace. The Applied Biosystems business is focused on the following markets: basic research, commercial research (pharmaceutical and biotechnology) and ... more
Applied Biosystems, 454 Life Sciences and Illumina Join 1000 Genomes Project
Leaders of the 1000 Genomes Project announced that three firms that have pioneered development of new sequencing technologies have joined the international effort to build the most detailed map to date of human genetic variation as a tool for medical research. The new participants are: Appl ... more
BIOTECON Diagnostics signs license agreement with Applera Corporation
Applera and BIOTECON Diagnostics (BCD) announced a non-exclusive, worldwide license agreement relating to PCR technology for Food Testing Applications and Genetically-Modified Organism (GMO) Testing Applications: BIOTECON Diagnostics has acquired important rights with the PCR licence. In ... more
Applied Biosystems Surpasses Industry Milestone in Lowering the Cost of Sequencing Human Genome
Applied Biosystems, an Applera Corporation business, announced a significant development in the quest to lower the cost of DNA sequencing. Scientists from the company have sequenced a human genome using its next-generation genetic analysis platform. The sequence data generated by this proje ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
